Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2017-09-28 Investor Presentation
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CPEng
Investor Presentation Classification · 1% confidence The document is a press release from AB Science SA dated September 28, 2017, announcing the presentation of clinical and preclinical data for their drug masitinib at 6 major international scientific meetings throughout late 2017 (e.g., World Congress of Neurology, NEALS Meeting, ANA Annual Meeting). It details the scientific findings, references external publications, and provides schedules for the presentations. This content is characteristic of an Investor Presentation (IP) or a detailed scientific update aimed at investors and researchers, rather than a formal regulatory filing (like 10-K or IR) or a brief earnings announcement (ER). Since it is a detailed presentation of scientific data and strategy updates for investors, 'Investor Presentation' (IP) is the most appropriate classification, even though it is distributed as a press release.
2017-09-28 English
CPFR
Investor Presentation Classification · 1% confidence The document is a press release from AB Science SA dated September 28, 2017. The primary content announces that clinical and preclinical data for their drug, masitinib, related to Amyotrophic Lateral Sclerosis (ALS) have been accepted for presentation at six major international conferences. It details the conferences, the presentation themes, and summarizes key clinical trial results. This is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement detailing scientific data presentation plans and related research findings, which aligns best with an Investor Presentation (IP) or a general announcement. Given the focus on presenting scientific data and trial results to the investment community via conference presentations, 'Investor Presentation' (IP) is the most fitting category, as it often encompasses detailed scientific updates shared with investors, even if delivered orally at a conference rather than a formal slide deck attachment. It is not a Report Publication Announcement (RPA) because it is announcing the *content* and *presentations*, not just the publication of a standalone report.
2017-09-28 French
CHMP Masto ENG
Regulatory Filings Classification · 1% confidence The document is a press release dated September 14, 2017, announcing that the CHMP (Committee for Medicinal Products for Human Use) of the EMA adopted a negative opinion regarding the marketing authorization for masitinib. This is a specific regulatory/legal development concerning a drug application, not a general financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It details the outcome of a regulatory review process and the company's subsequent plans. This type of announcement, detailing significant legal/regulatory actions or outcomes concerning the company's core operations (drug approval), fits best under the Legal Proceedings Report (LTR) category, as it concerns the outcome of a regulatory review process that could significantly impact the company's future operations and market standing, similar to a major lawsuit outcome. It is not a general regulatory filing (RNS) because it is highly specific to a legal/regulatory decision.
2017-09-14 English
CHMP Mastocytose FR
Legal Proceedings Report Classification · 1% confidence The document is a press release dated September 14, 2017, from the pharmaceutical company AB Science. The core subject is the announcement that the European Medicines Agency's Committee for Human Medicinal Products (CHMP) adopted a negative opinion regarding the marketing authorization application for masitinib. This is a significant regulatory/legal development concerning a product's approval status, which directly impacts the company's operations and future outlook. It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). It details a specific regulatory outcome and the company's response (planning a confirmatory study). This type of announcement, detailing legal/regulatory setbacks or progress concerning drug approval, fits best under 'Legal Proceedings Report' (LTR) as it concerns regulatory action/decision impacting the product's marketability, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the specific nature of the negative opinion from a major regulatory body (EMA/CHMP) regarding market authorization, LTR is a strong candidate, as it relates to a significant legal/regulatory hurdle. However, since it is a direct announcement about a regulatory decision rather than a lawsuit, and it is a formal press release, it is often categorized broadly. Comparing LTR (Legal Proceedings Report) and RNS (Regulatory Filings - fallback), LTR seems more precise for a drug approval outcome. If the document were purely about a lawsuit, LTR would be certain. Since it's about a regulatory decision that halts market entry, it is a significant regulatory event. Given the options, and that it is a specific announcement about a regulatory outcome that affects the business significantly, it is classified as a Legal/Regulatory Update. LTR covers significant lawsuits and regulatory actions. This is a regulatory action outcome. I will classify it as LTR.
2017-09-14 French
Pancreas Cancer Patent FR
Investor Presentation Classification · 1% confidence The document is a press release dated July 12, 2017, from AB Science. It announces the granting of a new European patent protecting the use of masitinib for pancreatic cancer until 2033. It also mentions that the recruitment goal for the confirmatory Phase 3 study (AB12005) has just been met. The content focuses heavily on intellectual property (patents), clinical trial progress, and scientific data related to a specific drug (masitinib). This type of announcement, detailing specific scientific/IP developments and clinical milestones, is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the strict definitions of ER, 10-K, or IR. Since it is a detailed announcement about strategy, development, and key data points (even referencing published study results), 'Investor Presentation' (IP) is the most appropriate fit among the specialized categories, as it serves to inform investors about core assets and progress, even if it's not a slide deck. It is not a formal regulatory filing like 10-K or a simple earnings release (ER). Given the focus on IP and clinical progress, IP is the best fit.
2017-07-12 French
Pancreas Cancer Patent EN
Investor Presentation Classification · 1% confidence The document is a press release dated July 12, 2017, announcing the issuance of a new European patent for the compound masitinib in treating pancreatic cancer. It details the patent protection extension, links this development to the recruitment target being reached in a Phase 3 clinical trial, and provides scientific background and forward-looking statements. This content is characteristic of an announcement related to intellectual property and ongoing clinical development, which falls under the scope of Investor Relations or general corporate updates. Since there is no specific category for 'Patent Grant Announcement,' and it is not a formal regulatory filing like a 10-K, 10-Q, or a specific financial release (ER, DIV), it is best classified as a general Regulatory Filing (RNS) or potentially Investor Presentation (IP) if it were a slide deck, but given the press release format focusing on IP news, RNS is the most appropriate general category for significant, non-standard corporate news that isn't a core financial report or management change. However, given the focus on Intellectual Property (IP) protection, the 'IP' code might be considered, but 'IP' is defined as 'Investor Presentation'. Since the core subject is the granting of a patent, which is a form of regulatory/legal protection announcement, RNS (Regulatory Filings/Miscellaneous) is the safest fallback, although 'IP' (Investor Presentation) is often used for detailed updates on strategy/pipeline. Given the strong focus on the patent itself, and the lack of a dedicated 'Patent' code, RNS is the most suitable general regulatory announcement category.
2017-07-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.